New combo therapy aims to stall prostate cancer spread

NCT ID NCT05893381

Recruiting now Disease control Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding a radioactive drug called Lu-PSMA to precise radiation therapy can better control prostate cancer that has spread to just 1-3 spots. About 70 men with hormone-sensitive prostate cancer will be randomly assigned to get radiation alone or radiation plus Lu-PSMA. The main goal is to see if the combination delays a rise in PSA levels, a marker of cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu-PSMA (a radioactive drug) and stereotactic radiotherapy
What this could lead to: If it works, this combination could delay cancer progression and the need for hormone therapy in men with a few prostate cancer metastases.
What could go wrong: This is a phase II trial with only 70 participants, so results are not definitive. The added radioactive drug may cause side effects like dry mouth or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UO Medicina Nucleare, AUSL della Romagna
RECRUITING

Cesena, FC, 47521, Italy

Contact Email: •••••@•••••
UO Medicina Nucleare, IRCCS IRST
RECRUITING

Meldola, FC, 47014, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.